Our key Figures
in 149 countries, including 5,000 in France.
5 major R&D areas
cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.
100 Million patients
treated daily with Servier medicinal products and generics.
33 drug candidates
in research and development, including 23 new molecular entities.
15 international centers of clinical development
and 3 research centers.
16 chemical and pharmaceutical production sites
producing chemicals and pharmaceuticals worldwide.
€4,2 billion euros in revenue
comprising €2.9 billion for branded drugs and €1.3 billion for generics.
25 % of turnover from Servier drugs is invested in R&D
No. 2 pharmaceutical company in France
no. 30 in the world; 3 research centres including 2 in France.
No.1 in cardiology in France
no. 2 in Europe, No. 5 in the world.
2nd leading preferred partner for research centers conducting clinical trials
According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies
Servier earned the highest score of A3++
As in previous years, this high score represents excellence in honoring financial commitments.
Participation reached 36,6% of the trade balance surplus in France
In pharmaceuticals and fine chemicals, amouting to €1.4 billion.